Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po


Iskalni niz: "avtor" (Branko Zakotnik) .

1 - 10 / 128
Na začetekNa prejšnjo stran12345678910Na naslednjo stranNa konec
Trends in population-based cancer survival in Slovenia
Vesna Zadnik, Tina Žagar, Katarina Lokar, Sonja Tomšič, Amela Duratović Konjević, Branko Zakotnik, 2021, izvirni znanstveni članek

Ključne besede: cancer burden, cancer survival, time trend, cancer registry
Objavljeno v DiRROS: 22.07.2024; Ogledov: 22; Prenosov: 7
.pdf Celotno besedilo (693,86 KB)
Gradivo ima več datotek! Več...

Poročilo državnega programa obvladovanja raka za leto 2023
Sonja Tomšič, Janez Žgajnar, Katarina Plantosar, Amela Duratović Konjević, Katarina Torkar, Branko Zakotnik, 2024, objavljeni strokovni prispevek na konferenci

Ključne besede: obvladovanje raka, državni program, onkologija
Objavljeno v DiRROS: 06.06.2024; Ogledov: 122; Prenosov: 53
.pdf Celotno besedilo (66,82 KB)

Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy
Erika Šoba, Marjan Budihna, Alojz Šmid, Nina Gale, Hotimir Lešničar, Branko Zakotnik, Primož Strojan, 2015, izvirni znanstveni članek

Povzetek: The aim of the study was to investigate how the expression of tumor markers p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31 influenced the outcome of advanced inoperable oropharyngeal carcinoma patients, treated with concomitant radiochemotherapy. Patients and methods. The pretreatment biopsy specimens of 74 consecutive patients with inoperable stage IV oropharyngeal squamous cell carcinoma treated with concomitant radiochemotherapy were in retrospective study processed by immunochemistry for p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31. Disease-free survival (DFS) was assessed according to the expression of tumor markers. Results. Patients with a high expression of p21 (%10%), p27 (>50%), Ki-67 (>50%), CD31 (>130 vessels/mm2) and low expression of p53 (<10%), cyclin D1 (<10%) and EGFR (<10%) (favorable levels - FL) had better DFS than patients with a low expression of p21 (<10%), p27 (%50%), Ki-67 (%50%), CD31 (<130 vessels/mm2) and high expression of p53 (%10%), cyclin D1 (%10%) and EGFR (%10%) (unfavorable levels - UL). However, statistical significance in survival between FL and UL was achieved only for p27 and cyclin D1. DFS significantly decreased with an increasing number of markers with an unfavorable level per tumor (1%4 vs. 5%7) (78% vs. 32%, respectively; p = 0.004). The number of markers per tumor with UL of expression retained prognostic significance also in multivariate analysis. Conclusions. Statistical significance in survival between FL and UL emerged only for p27 and cyclin D1. The number of markers per tumor with UL of expression was an independent prognostic factor for an adverse outcome .
Ključne besede: oropharynx, radiochemotherapy, tumor markers
Objavljeno v DiRROS: 22.04.2024; Ogledov: 250; Prenosov: 64
.pdf Celotno besedilo (560,05 KB)

Effectiveness of adjuvant trastuzumab in daily clinical practice
Erika Matos, Branko Zakotnik, Cvetka Grašič-Kuhar, 2014, izvirni znanstveni članek

Povzetek: Background. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice. Patients and methods. An analysis of tumour and patient characteristics, type of treatment and outcome (relapse free and overall survival) of 313 patients (median age 52 years) treated at the Institute of Oncology Ljubljana in years 2005-2009 was performed. Results. Median follow-up was 4.4 years. Sixty-one patients relapsed and 24 died. Three and four years relapse free survival was 84.2% and 80.8% and the overall survival was 94.4% and 92.5%, respectively. Independent prognostic factors for relapse were tumour grade (HR 2.10; 95% CI 1.07-4.14; p = 0.031) and nodal stage (HR 1.35; 1.16-1.56; p < 0.0001) and for the overall survival nodal stage only (HR 1.36; 1.05-1.78; p = 0.021). Conclusions. The outcome in patients with adjuvant trastuzumab in daily clinical practice, treated by medical oncologists, is comparable to results obtained in international adjuvant studies.
Ključne besede: breast cancer, trastuzumab, adjuvant, clinical practice
Objavljeno v DiRROS: 11.04.2024; Ogledov: 453; Prenosov: 352
.pdf Celotno besedilo (549,44 KB)

Digital ischemic events related to gemcitabine : report of two cases and a systematic review
Cvetka Grašič-Kuhar, Tanja Mesti, Branko Zakotnik, 2010, izvirni znanstveni članek

Objavljeno v DiRROS: 15.03.2024; Ogledov: 226; Prenosov: 73
.pdf Celotno besedilo (621,57 KB)

Preoperative concomitant chemoradiotherapy in esophageal cancer
Boštjan Šeruga, Mihael Sok, Janez Eržen, Jože Jerman, Boris Jančar, Branko Zakotnik, 2006, izvirni znanstveni članek

Povzetek: Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survivalof patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of preoperative CRT in patients with locally advanced esophageal cancer was analysed as well as the influence of pCR on thesuraival. Patients and metkods From 1996 to 2002 41 patients with locoregionally confined esophageal cancerwere treated with cisplatin 75 mgžm2 and 5-FU 1000 mgžm2 as 4 day contonuous infusion starting on days 1. and 22. with concorrtitant radiotherapy 4500 cGy, 200-300 cGyžday. Esophagectomy followed 4-5 weeks after radiotherapy. After the surgery patients were followed-up regularly at 3-6 months intervals. Results. The pCR was achieved in 26.8% of patients. The overall median survival time was 18 months for all patients, 21.2 months for patients who achieved pCR and 16 months in those with residual disease (p= 0,79). Postoperative mortality rate was 22%. The median dose intensity for cisplatin was 92% and for 5-FU 71.5 of the planned dose. Disease recurred most often locoregionally (31.7%) and the overall recurrence rate was 43.9. Conclusion. Modern radiation techniques and the adequate dose intensity could further improve the locoregional control. The selection of patients without comorbid conditions and without already present distant metastases is essential for this combined treatment approach.
Objavljeno v DiRROS: 15.02.2024; Ogledov: 281; Prenosov: 64
.pdf Celotno besedilo (123,83 KB)

Early glottic cancer : the influence of primary therapy on ultimate organ preservation
Hotimir Lešničar, Alojz Šmid, Branko Zakotnik, 1997, izvirni znanstveni članek

Objavljeno v DiRROS: 16.01.2024; Ogledov: 293; Prenosov: 63
.pdf Celotno besedilo (215,84 KB)

Iskanje izvedeno v 2.82 sek.
Na vrh